1-[5-ETHYL-2-HYDROXY-4-[[6-METHYL-6-(1H-TETRAZOL-5-YL)HEPTYL]OXY]PHENYL]ETHANONE
生物活性靶点体外研究体内研究 用途与合成方法 MSDS 1-[5-ETHYL-2-HYDROXY-4-[[6-METHYL-6-(1H-TETRAZOL-5-YL)HEPTYL]OXY]PHENYL]ETHANONE价格(试剂级) 上下游产品信息
| 中文名称 | 1-[5-ETHYL-2-HYDROXY-4-[[6-METHYL-6-(1H-TETRAZOL-5-YL)HEPTYL]OXY]PHENYL]ETHANONE |
|---|---|
| 中文同义词 | 化合物LY 255283;LY255283游离态;1-(5-乙基-2-羟基-4-((6-甲基-6-(2H-四唑-5-基)庚基)氧基)苯基)乙-1-酮;LY255283,BLT2受体拮抗剂 |
| 英文名称 | 1-[5-ETHYL-2-HYDROXY-4-[[6-METHYL-6-(1H-TETRAZOL-5-YL)HEPTYL]OXY]PHENYL]ETHANONE |
| 英文同义词 | LY 255283;1-[5-ETHYL-2-HYDROXY-4-[[6-METHYL-6-(1H-TETRAZOL-5-YL)HEPTYL]OXY]PHENYL]ETHANONE;1-[5-ETHYL-2-HYDROXY-4-[[6-METHYL-6-(1H-TETRAZOLE-5-YL)HEPTYL]OXY]PHENYL]-ETHANONE;5'-Ethyl-2'-hydroxy-4'-[6-methyl-6-(1H-tetrazol-5-yl)heptyloxy]acetophenone;CGS 23356;1-[5-ethyl-2-hydroxy-4-[6-methyl-6-(2H-tetrazol-5-yl)heptoxy]phenyl]ethanone;Ethanone, 1-[5-ethyl-2-hydroxy-4-[[6-methyl-6-(2H-tetrazol-5-yl)heptyl]oxy]phenyl]-;1-(5-Ethyl-2-hydroxy-4-((6-methyl-6-(2H-tetrazol-5-yl)heptyl)oxy)phenyl)ethan-1-one |
| CAS号 | 117690-79-6 |
| 分子式 | C19H28N4O3 |
| 分子量 | 360.45 |
| EINECS号 | |
| 相关类别 | Prostanoid receptor and related |
| Mol文件 | 117690-79-6.mol |
| 结构式 | ![1-[5-ETHYL-2-HYDROXY-4-[[6-METHYL-6-(1H-TETRAZOL-5-YL)HEPTYL]OXY]PHENYL]ETHANONE 结构式](CAS/GIF/117690-79-6.gif) |
1-[5-ETHYL-2-HYDROXY-4-[[6-METHYL-6-(1H-TETRAZOL-5-YL)HEPTYL]OXY]PHENYL]ETHANONE 性质
| 熔点 | 160-162 °C |
|---|---|
| 沸点 | 573.4±60.0 °C(Predicted) |
| 密度 | 1.157±0.06 g/cm3(Predicted) |
| 储存条件 | Store at +4°C |
| 溶解度 | 二甲基亚砜：>20mg/mL |
| 形态 | 粉末 |
| 酸度系数(pKa) | 5.11±0.10(Predicted) |
| 颜色 | 灰白色至浅黄色 |
LY255283 是一种 leukotriene B4 (LTB4) receptor (BLT2) 的拮抗剂，可将 [3H]LTB4 从其在肺膜上的结合位点置换，pKi为7.0。
| Target | Value |
|
BLT2
(Cell-free assay) | 7.0(pKi) |
LY255283 competitively reduces conlractilc responses of lung parcnchyma to LTB, (pA
2
= 7.2).
LY255283 (10 μM, 7 days) significantly suppresses the invasiveness of highly aggressive 253 J-BV bladder cancer cells.
Cell Viability Assay
| Cell Line: | 253 J-BV cells. |
| Concentration: | 5 or 10 μM. |
| Incubation Time: | 7 days. |
| Result: | Inhibition of BLT2 signaling attenuates aggressive migration by 253 J-BV cells. |
LY255283 (3, 30 mg/kg) ameliorates lipopolysaccharide-induced ARDS in pigs, possibly by blocking the recruitment of activated PMNs into alveoli in a dose-dependent fashion.
LY255283 (2.5 mg/kg, ip) inhibits transitional cell carcinoma metastasis in mice models. The result suggests that a BLT2–Nox–ROS–NF–κB cascade plays a critical role in bladder cancer invasion and metastasis.
| Animal Model: | Mice (253 J-BV cells injected). |
| Dosage: | 2.5 mg/kg. |
| Administration: | IP injected 3 and 5 days after injection of cells. |
| Result: | By 12 weeks after injection, in mice treated with LY255283 only 0-3 nodules formed per lung, and histological analysis confirmed that the number of micrometastatic lesions was markedly reduced. |
安全信息
| WGK Germany | 2 |
|---|
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024/01/25 | HY-15744 | LY255283 | 1 mg | 636元 | |
| 2024/01/25 | HY-15744 | 1-[5-ETHYL-2-HYDROXY-4-[[6-METHYL-6-(1H-TETRAZOL-5-YL)HEPTYL]OXY]PHENYL]ETHANONE LY255283 | 117690-79-6 | 5mg | 1400元 |